Resources from the same session
A phase I study to evaluate safety and efficacy of BPI-7711 in EGFRm+/T790M+ advanced or recurrent NSCLC patients
Presenter: Sheng Yang
Session: Mini Oral session - Thoracic cancers
Resources:
Slides
Webcast
Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
Presenter: Ross Soo
Session: Mini Oral session - Thoracic cancers
Resources:
Slides
Webcast
Induction gefitinib followed by standard chemoradiotherapy in locally advanced (LA) non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations: The LOGIK0902/OLCSG0905 intergroup phase II study
Presenter: Sho Saeki
Session: Mini Oral session - Thoracic cancers
Resources:
Slides
Webcast
Phase II study of fruquintinib plus gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations
Presenter: shun Lu
Session: Mini Oral session - Thoracic cancers
Resources:
Slides
Survival and treatment patterns in patients (pts) with locally advanced or metastatic NSCLC treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIS): Analysis of US insurance claims databases
Presenter: Ross Soo
Session: Mini Oral session - Thoracic cancers
Resources:
Slides
Webcast
Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
Presenter: Tony S.K. Mok
Session: Mini Oral session - Thoracic cancers
Resources:
Slides
Webcast
Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC
Presenter: Ying Cheng
Session: Mini Oral session - Thoracic cancers
Resources:
Slides
Webcast
Discussion led by moderators
Presenter: Byoung Chul Cho
Session: Mini Oral session - Thoracic cancers
Resources:
Slides
Webcast